Sagimet Biosciences announces presentations at MASH Drug Development Summit

Sagimet Biosciences (SGMT) announced that the Company will give two oral presentations and participate in a drug development panel at the 9th Annual MASH Drug Development Summit taking place September 29-October 1, 2025 in Boston, MA. The two presentations will cover combination treatment with a FASN inhibitor, and AI-based digital pathology to evaluate denifanstat anti-fibrotic effect in MASH patients respectively. Presentation Title: Highlighting Mechanism of Action of FASN Inhibitor Denifanstat in MASH: Key Highlights: This presentation will focus on reviewing the preclinical activity of a FASN inhibitor combined with semaglutide or resmetirom and will highlight the efficacy of denifanstat when added to background GLP1 treatment in the Phase 2b FASCINATE-2 study. Dr. O’Farrell will also cover the planned Phase 1 PK study of denifanstat and resmetirom. Panel Discussion: Designing Therapies with Novel Mechanisms & Predictive Biomarkers to Holistically Improve Treatment for Better Patient Outcomes. Presentation Title: Utilizing AI-Based Digital Pathology to Evaluate Denifanstat’s Anti-Fibrotic Effect in MASH Patients with Advanced Fibrosis. Key Highlights: This presentation will discuss the mechanism of action for denifanstat and its robust anti-fibrotic effect in MASH patients with F3 fibrosis as well as the application of digital pathology techniques to assess this anti-fibrotic effect. Dr. Tsai will also discuss the use of zonal analysis to explore denifanstat’s potential to offer long-term clinical benefit.